Amicus Therapeutics Inc., of Cranbury, N.J., said it closed its offering of common stock with gross expected to be $201 million. The company expects to use the net proceeds of the offering for investment in the development of an expanded gene therapy pipeline, manufacturing capabilities for Pompe biologic AT-GAA and gene therapy product candidates.